Illuminare Biotechnologies

Illuminare Biotechnologies is a preclinical stage biotechnology company specializing in intraoperative nerve visualization to mitigate the risk of nerve damage during surgeries. The company's core product, Illuminare 1, is a small molecule designed to provide immediate and sustained nerve illumination, enhancing real-time visualization for surgeons. Approved by the FDA for an Investigational New Drug (IND) application in April 2021, Illuminare 1 is set to enter its first human phase 1 clinical trial at Memorial Sloan Kettering Cancer Center. Illuminare Biotechnologies primarily serves the medical and surgical community, aiming to improve surgical outcomes and patient safety. The company operates within the biotechnology and medical devices market, leveraging its proprietary technology to create value. Revenue generation is expected through the commercialization of Illuminare 1 and potential future products, targeting hospitals, surgical centers, and healthcare providers.

Keywords: nerve visualization, intraoperative, biotechnology, nerve damage, small molecule, FDA approved, clinical trial, surgical safety, medical devices, proprietary technology.